Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission (EC) has granted conditional marketing authorisation (CMA) to the Janssen Pharmaceutical Companies of Johnson & Johnson’s Talvey (talquetamab) for the treatment of relapsed and refractory multiple myeloma (RRMM) in adult patients who received a minimum of three prior lines of therapies.
Talvey is intended for the treatment of relapsed and refractory multiple myeloma. Credit: www.scientificanimations.com/commons.wikimedia.org.
Subscribe to our email newsletter
These therapies include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Talvey recently received the US Food and Drug Administration’s approval for the same indication in adults who received at least four prior lines of therapy.
It is a bispecific antibody that targets T-cell CD-3 receptors and G protein-coupled receptor class C group 5 member D (GPRC5D).
After an initial step-up phase, talquetamab is indicated for use as a weekly (QW) or biweekly (Q2W) subcutaneous injection.
The CMA was based on the safety and efficacy data, as demonstrated in the Phase I/II MonumenTAL-1 study.
Nearly 145 patients received 0.8 mg/kg Q2W while 143 were treated with 0.4 mg/kg QW. Both the groups receiving a median of five (range, 2-17) prior lines showed meaningful overall response rates.
Some of the most common adverse events reported during the study include hypogammaglobulinaemia, dysgeusia, cytokine release syndrome, and nail disorders.
Janssen Research & Development Oncology, global therapeutic area head Peter Lebowitz said: “As our fifth innovative therapy and second bispecific antibody for multiple myeloma, talquetamab is testament to our continued ambition to discover and develop a portfolio of innovative and complementary therapies.
“We now look forward to bringing this new option to patients and physicians.”
